Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Prometheus Biosciences Inc (RXDX)
Prometheus Biosciences Inc (RXDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,213,090
  • Shares Outstanding, K 47,530
  • Annual Sales, $ 6,810 K
  • Annual Income, $ -141,750 K
  • 60-Month Beta -0.49
  • Price/Sales 770.02
  • Price/Cash Flow N/A
  • Price/Book 6.84
Trade RXDX with:

Options Overview Details

View History
  • Implied Volatility 66.42% ( +0.07%)
  • Historical Volatility 44.15%
  • IV Percentile 25%
  • IV Rank 6.19%
  • IV High 332.22% on 11/18/22
  • IV Low 48.88% on 06/06/22
  • Put/Call Vol Ratio 0.27
  • Today's Volume 79
  • Volume Avg (30-Day) 374
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 14,745
  • Open Int (30-Day) 13,585

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate -0.92
  • Number of Estimates 5
  • High Estimate -0.78
  • Low Estimate -1.04
  • Prior Year -0.82
  • Growth Rate Est. (year over year) -12.20%

Price Performance

See More
Period Period Low Period High Performance
1-Month
104.89 +6.72%
on 03/23/23
129.60 -13.63%
on 03/07/23
-10.45 (-8.54%)
since 02/28/23
3-Month
103.33 +8.33%
on 01/06/23
129.60 -13.63%
on 03/07/23
+2.81 (+2.57%)
since 12/28/22
52-Week
21.50 +420.65%
on 05/12/22
129.60 -13.63%
on 03/07/23
+73.73 (+192.96%)
since 03/28/22

Most Recent Stories

More News
Prometheus Biosciences, Inc. (RXDX) Reports Q4 Loss, Misses Revenue Estimates

Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of 1.10% and 6.71%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...

RXDX : 111.56 (+1.71%)
AKYA : 8.26 (+1.72%)
Denali Therapeutics Inc. (DNLI) Surges 5.8%: Is This an Indication of Further Gains?

Denali Therapeutics Inc. (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price...

DNLI : 23.13 (+1.36%)
RXDX : 111.56 (+1.71%)
Wall Street Analysts Think Prometheus Biosciences, Inc. (RXDX) Could Surge 33.49%: Read This Before Placing a Bet

The mean of analysts' price targets for Prometheus Biosciences, Inc. (RXDX) points to a 33.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

RXDX : 111.56 (+1.71%)
Zacks Investment Ideas feature highlights: XBI, Catalyst Pharma, Prometheus Biosciences, Sage Therapeutics and IBB

XBI, Catalyst Pharma, Prometheus Biosciences, Sage Therapeutics and IBB are part of the Zacks Investment Ideas article.

IBB : 127.39 (+1.06%)
CPRX : 16.63 (+1.59%)
RXDX : 111.56 (+1.71%)
SAGE : 43.53 (+4.19%)
XBI : 75.82 (+1.84%)
Biotech's Blockbuster Week: 3 Stocks to Watch

In a strong week for the market, biotech dominated. Today we will cover 3 promising stocks in the space.

IBB : 127.39 (+1.06%)
CPRX : 16.63 (+1.59%)
RXDX : 111.56 (+1.71%)
SAGE : 43.53 (+4.19%)
XBI : 75.82 (+1.84%)
Wall Street Analysts Believe Prometheus Biosciences, Inc. (RXDX) Could Rally 26.51%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 26.5% in Prometheus Biosciences, Inc. (RXDX). While the effectiveness of this highly sought-after metric is questionable,...

RXDX : 111.56 (+1.71%)
Is Prometheus Biosciences a Good Stock to Buy Right Now?

This biotech stock just jumped over 180% in a single day, and investors want to know if there could be more big gains ahead.

RXDX : 111.56 (+1.71%)
PFE : 40.10 (+0.28%)
TEVA : 8.81 (+0.57%)
Why Shares of Prometheus Biosciences Are Soaring This Week

The clinical-stage biotech that specializes in IBD therapies announced positive news regarding two trials for its lead therapy.

RXDX : 111.56 (+1.71%)
Biotechs Race for New Treatments as Breast Cancer Therapeutics Market Could Reach $15 Billion by 2028

EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:GILD),(NYSE:BMY),(NASDAQ:RXDS),(NASDAQ:RNAZ) EQNX::TICKER_END

ONCY : 1.2000 (-0.83%)
ONC.TO : 1.63 (-0.61%)
GILD : 81.19 (+0.27%)
RXDX : 111.56 (+1.71%)
RNAZ : 0.3250 (+3.93%)
BMY : 67.99 (-0.31%)
Biotechs Race for New Treatments as Breast Cancer Therapeutics Market Could Reach $15 Billion by 2028

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - According to a report from Global Market Insights the Breast Cancer Therapeutics Market size, which...

ONC.TO : 1.63 (-0.61%)
ONCY : 1.2000 (-0.83%)
GILD : 81.19 (+0.27%)
BMY : 67.99 (-0.31%)
RXDX : 111.56 (+1.71%)
RNAZ : 0.3250 (+3.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Prometheus Biosciences Inc. is a biotechnology company. It involved in the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease. Prometheus Biosciences Inc. is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 114.05
2nd Resistance Point 112.97
1st Resistance Point 111.33
Last Price 111.56
1st Support Level 108.61
2nd Support Level 107.53
3rd Support Level 105.89

See More

52-Week High 129.60
Last Price 111.56
Fibonacci 61.8% 88.31
Fibonacci 50% 75.55
Fibonacci 38.2% 62.79
52-Week Low 21.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar